Filings & corporate actions
76 results filed
CSVNext results · Q2 FY27
Expected 10 Nov 2026 – 14 Nov 2026
Estimate: filed 41–45 days after quarter end, last 5 times
Dividend
₹6.00 per share · last 7 Aug 2026
2026
- 13 AugresultsResults · Q1 FY27 · consolidated and standalone-3.5%NSE
- 7 AugdividendDividend · ₹6.00 per share+0.1%
- 17 JulshareholdingShareholding · 30 Jun 2026+0.6%NSE
- 29 MayresultsResults · Q4 FY26 · consolidated and standalone-2.2%NSE
- 8 AprshareholdingShareholding · 31 Mar 2026+0.2%NSE
- 13 FebresultsResults · Q3 FY26 · consolidated and standalone+0.7%NSE
- 14 JanshareholdingShareholding · 31 Dec 2025+0.6%NSE
Reaction to results · all yearsrose on day 0 in 40 of 76 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q1 FY27 | 13 Aug 2026 | -3.5% | +6.4% | +9.6% | 1.4× |
| Q4 FY26 | 29 May 2026 | -2.2% | +8.2% | +11.6% | 0.8× |
| Q3 FY26 | 13 Feb 2026 | +0.7% | -0.8% | +5.4% | 1.2× |
| Q2 FY26 | 13 Nov 2025 | +13.6% | +10.9% | +12.6% | 29.2× |
| Q1 FY26 | 11 Aug 2025 | +3.0% | +2.5% | -1.8% | 1.4× |
| Q4 FY25 | 29 May 2025 | -3.1% | -6.7% | -9.4% | 1.6× |
| Q3 FY25 | 13 Feb 2025 | -1.8% | -3.1% | -9.6% | 2.8× |
| Q2 FY25 | 14 Nov 2024 | +2.0% | +1.9% | +1.4% | 1.1× |
| Q1 FY25 | 13 Aug 2024 | -3.4% | +0.4% | +4.3% | 2.2× |
| Q4 FY24 | 29 May 2024 | -3.4% | -10.2% | -12.7% | 1.9× |
| Q3 FY24 | 14 Feb 2024 | -0.2% | +6.6% | +2.5% | 1.4× |
| Q2 FY24 | 10 Nov 2023 | -1.7% | +1.0% | +3.9% | 0.1× |
| Q1 FY24 | 10 Aug 2023 | +0.7% | -1.5% | -0.1% | 1.9× |
| Q4 FY23 | 29 May 2023 | -0.2% | +8.6% | +6.8% | 1.5× |
| Q3 FY23 | 14 Feb 2023 | -0.7% | -3.4% | -8.0% | 1.6× |
| Q2 FY23 | 11 Nov 2022 | +0.2% | +0.1% | -0.7% | 1.1× |
| Q1 FY23 | 10 Aug 2022 | +2.5% | -7.2% | -11.7% | 1.3× |
| Q4 FY22 | 25 May 2022 | -1.8% | -6.9% | -7.0% | 2.1× |
| Q3 FY22 | 14 Feb 2022 | +2.5% | -0.3% | +3.7% | 3.0× |
| Q2 FY22 | 13 Nov 2021 | -0.9% | -7.3% | -8.5% | 1.9× |
| Q1 FY22 | 5 Aug 2021 | +1.7% | +11.7% | +17.1% | 1.7× |
| Q4 FY21 | 28 May 2021 | +2.1% | +0.7% | -0.6% | 1.6× |
| Q3 FY21 | 4 Feb 2021 | -3.5% | -5.2% | -3.9% | 1.0× |
| Q2 FY21 | 7 Nov 2020 | -3.2% | -10.0% | -3.5% | 2.9× |
| Q1 FY21 | 10 Aug 2020 | -4.5% | -4.5% | -6.1% | 3.3× |
| Q4 FY20 | 17 Jun 2020 | -2.0% | +3.6% | +3.4% | 1.0× |
| Q3 FY20 | 13 Feb 2020 | +7.2% | +9.9% | -1.6% | 3.8× |
| Q2 FY20 | 8 Nov 2019 | +0.6% | +9.1% | +2.8% | 2.9× |
| Q1 FY20 | 14 Aug 2019 | +0.5% | +2.7% | +1.3% | 0.3× |
| Q4 FY19 | 30 May 2019 | +0.6% | +1.1% | -1.2% | 0.7× |
| Q3 FY19 | 19 Feb 2019 | -0.7% | -0.2% | +15.3% | 0.7× |
| Q2 FY19 | 27 Nov 2018 | +0.1% | +1.3% | +0.3% | 0.8× |
| Q1 FY19 | 24 Aug 2018 | +2.0% | +2.9% | -6.0% | 1.1× |
| Q4 FY18 | 26 Jun 2018 | +1.0% | +7.4% | +13.3% | 1.3× |
| Q3 FY18 | 28 Feb 2018 | 0.0% | -0.8% | -1.2% | 0.3× |
| Q2 FY18 | 22 Nov 2017 | +0.4% | +0.7% | +11.4% | 0.3× |
| Q1 FY18 | 21 Aug 2017 | -0.2% | +1.6% | +20.4% | 1.7× |
| Q4 FY17 | 20 Jun 2017 | +0.2% | +1.6% | +1.8% | 2.4× |
| Q3 FY17 | 17 Feb 2017 | +3.8% | +4.6% | +4.9% | 3.1× |
| Q2 FY17 | 15 Nov 2016 | -3.8% | -3.0% | -3.9% | 1.2× |
| Q1 FY17 | 20 Sept 2016 | 0.0% | +1.3% | +3.8% | 0.5× |
| Q4 FY16 | 31 May 2016 | +0.4% | +0.8% | +14.0% | 1.3× |
| Q3 FY16 | 9 Feb 2016 | +0.7% | -6.5% | -15.5% | 2.4× |
| Q2 FY16 | 2 Nov 2015 | -2.3% | -7.1% | -0.3% | 0.9× |
| Q1 FY16 | 3 Aug 2015 | +0.6% | +5.3% | +9.0% | 0.9× |
| Q4 FY15 | 3 Jun 2015 | -3.0% | -1.7% | +7.9% | 1.3× |
| Q3 FY15 | 9 Feb 2015 | +1.9% | +9.7% | +16.9% | 2.4× |
| Q2 FY15 | 19 Nov 2014 | -0.4% | +0.7% | +4.8% | 0.2× |
| Q1 FY15 | 14 Aug 2014 | -0.1% | +3.7% | +12.0% | 0.2× |
| Q4 FY14 | 31 May 2014 | +0.1% | +2.4% | +11.3% | 1.2× |
| Q3 FY14 | 29 Jan 2014 | +2.2% | +2.6% | +11.3% | 3.6× |
| Q2 FY14 | 6 Nov 2013 | +1.9% | -0.7% | -5.1% | 0.9× |
| Q1 FY14 | 31 Jul 2013 | -0.2% | -3.5% | -3.1% | 0.7× |
| Q4 FY13 | 11 Jun 2013 | +4.8% | +12.2% | +11.0% | 6.8× |
| Q3 FY13 | 30 Jan 2013 | -1.1% | -0.2% | +1.4% | 2.6× |
| Q2 FY13 | 25 Oct 2012 | -0.5% | +1.5% | -3.8% | 1.7× |
| Q1 FY13 | 31 Jul 2012 | +0.6% | +4.4% | +8.6% | 1.2× |
| Q4 FY12 | 2 Jun 2012 | -1.0% | +1.5% | +5.0% | 0.2× |
| Q3 FY12 | 31 Jan 2012 | +5.5% | +13.6% | +21.6% | 5.7× |
| Q2 FY12 | 31 Oct 2011 | +5.6% | +11.6% | +7.1% | 2.7× |
| Q1 FY12 | 28 Jul 2011 | -3.3% | -4.2% | -9.9% | 8.6× |
| Q3 FY11 | 25 Jan 2011 | -2.2% | -8.1% | -10.6% | 4.0× |
| Q2 FY11 | 22 Oct 2010 | +0.1% | +9.2% | +11.3% | 2.5× |
| Q1 FY11 | 29 Jul 2010 | -2.1% | +0.5% | +4.0% | 2.5× |
| Q3 FY10 | 21 Jan 2010 | -0.3% | -4.4% | -5.4% | 1.3× |
| Q2 FY10 | 27 Oct 2009 | +2.0% | +7.7% | +11.2% | 2.5× |
| Q1 FY10 | 30 Jul 2009 | +5.1% | +6.7% | +20.3% | 5.4× |
| Q4 FY09 | 28 May 2009 | -4.2% | +8.4% | +0.6% | 3.8× |
| Q3 FY09 | 22 Jan 2009 | -5.0% | -0.8% | -7.1% | 14.0× |
| Q2 FY09 | 31 Oct 2008 | +8.3% | +11.5% | -8.8% | 3.5× |
| Q1 FY09 | 25 Jul 2008 | +0.1% | +0.7% | +5.7% | 0.4× |
| Q4 FY08 | 29 May 2008 | +1.4% | -0.4% | +0.4% | 1.3× |
| Q3 FY08 | 19 Jan 2008 | -1.5% | -6.5% | -15.5% | 2.1× |
| Q2 FY08 | 29 Oct 2007 | +0.6% | +10.5% | -0.7% | 1.6× |
| Q1 FY08 | 20 Jul 2007 | +0.7% | -0.8% | -3.7% | 1.3× |
| Q4 FY07 | 25 May 2007 | +0.3% | +1.5% | +16.3% | 2.9× |
| Average | +0.3% | +1.5% | +2.4% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q1 FY27
CSVRevenue YoY+20.8%
Profit YoY+82.2%
Interest cost YoY—
Revenue QoQ+16.7%
Profit QoQ+38.3%
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Profit | — | — | — | — | — | — |
Key data
CSVOpen1,951.20
Day range1,932.00 – 1,965.00
52-week range1,251.60 – 2,038.00
From 52w high-4.5%
RSI (14)51.0
ATR (14)57.12
Volume2.72L
Avg volume (20D)2.49L
Rel volume1.09×
Volatility (1Y)29.4%
Turnover₹52.8Cr
SMA 50 / 2001,890.31 / 1,633.87
Delivery percentage
Latest · 6 Oct 202678.7%
20-day avg57.0%
1-year avg49.7%
Percentile (own history)98th
Range11.8–93.9%
Sessions1,731
Over the last 20 sessions IPCALAB settled 57.0% of its traded quantity, which is above average for an NSE equity. Its one-year average is 49.7%, so recent sessions are running 7.4 points higher than usual. The latest session ranks higher than 98% of the 1,731 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
IndustryPharmaceuticals
Performance returns
CSV| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | -0.30% | +1.37% | -0.54% | +8.50% | +30.72% | +41.88% |
Valuation
CSVMarket cap₹49,358 Cr
P/E (TTM)35.9
EPS (TTM)54.20
Shares outstanding25.37Cr
Listed8 Feb 1995
Ownership
CSVPromoter—
Promoter Δ QoQ—
Public—
FII—
DII—
Pledged—
Quarterly results · consolidated
CSV| Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 2,556.5 | 2,392.5 | 2,388.5 | 2,788.1 |
| YoY chg | — | — | +6.3% | +20.8% |
| Net profit (₹ Cr) | 280.5 | 363.7 | 306.7 | 424.3 |
| YoY chg | — | — | +379.3% | +82.2% |
| Net margin | 11.0% | 15.2% | 12.8% | 15.2% |
| EPS | 11.14 | 12.86 | 11.79 | 15.84 |
Shareholding over time
CSVBy quarter
30 Jun 2026 · promoter 44.72% · public 55.28%2021-092026-06
- Promoter
- Public and others
- Promoter
- 44.72%
- Public
- 55.28%
- Promoter change
- 0.00 pp
- Filed
- 17 Jul 2026
- FII
- 10.73%
- DII
- 37.37%
- Promoter pledged
- 0.00%
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.
Financials · quarterly statement
CSV₹ crore, as filed
| Q2 FY24 | Q3 FY24 | Q4 FY24A | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25A | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26A | Q1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 2,034.0 | 2,052.9 | 2,033.0 | 2,092.6 | 2,354.9 | 2,245.4 | 2,246.7 | 2,308.9 | 2,556.5 | 2,392.5 | 2,388.5 | 2,788.1 | |
| Other income | 38.6 | 22.5 | 18.9 | 20.6 | 26.3 | 20.1 | 25.8 | 32.7 | 27.9 | 20.2 | 93.7 | 25.3 | |
| Total income | 2,072.5 | 2,075.3 | 2,051.9 | 2,113.2 | 2,381.2 | 2,265.5 | 2,272.5 | 2,341.5 | 2,584.4 | 2,412.7 | 2,482.2 | 2,813.4 | |
| Total expenses | 1,847.2 | 1,854.4 | 1,838.6 | 1,822.9 | 2,036.3 | 1,897.6 | 1,939.5 | 2,011.0 | 2,134.5 | 1,984.4 | 2,032.0 | 2,241.3 | |
| └ Finance costs | 44.1 | 33.4 | 29.4 | 24.1 | 22.6 | 16.8 | 21.5 | 18.5 | 19.6 | 17.6 | 20.2 | 11.9 | |
| └ Depreciation | 90.3 | 99.5 | 98.1 | 98.9 | 100.4 | 98.5 | 100.1 | 100.1 | 103.3 | 107.6 | 107.1 | 110.8 | |
| Profit before tax | 225.4 | 288.9 | 76.6 | 290.4 | 344.8 | 367.9 | 128.0 | 330.5 | 391.6 | 446.0 | 404.5 | 572.1 | |
| Tax expense | 87.9 | 66.2 | 73.7 | 91.4 | 99.4 | 90.6 | 62.2 | 96.1 | 108.1 | 81.9 | 95.1 | 149.3 | |
| Net profit | 136.5 | 221.0 | 1.3 | 199.1 | 245.8 | 276.4 | 64.0 | 232.9 | 280.5 | 363.7 | 306.7 | 424.3 | |
| EPS | 5.72 | 7.09 | 2.35 | 7.58 | 9.05 | 9.78 | 2.67 | 9.19 | 11.14 | 12.86 | 11.79 | 15.84 | |
| Net margin | 6.71% | 10.77% | 0.07% | 9.52% | 10.44% | 12.31% | 2.85% | 10.09% | 10.97% | 15.20% | 12.84% | 15.22% | |
| PBT margin | 11.08% | 14.07% | 3.77% | 13.88% | 14.64% | 16.39% | 5.70% | 14.31% | 15.32% | 18.64% | 16.93% | 20.52% | |
| Tax rate | 39.01% | 22.93% | 96.20% | 31.48% | 28.82% | 24.62% | 48.61% | 29.07% | 27.60% | 18.37% | 23.50% | 26.09% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 13 Aug 2026.
IPCALAB at a glance
- IPCALAB closed at ₹1,945.5 on 6 Oct 2026, -0.30% on the day, +41.9% over one year, 4.5% below its 52-week high of ₹2,038.
- Delivery was 78.7% of traded quantity on 6 Oct 2026, the 98th percentile of its own 1,731 sessions with a reading (20-session average 57.0%, 1-year average 49.7%).
- Market capitalisation is ₹49,358 crore at a trailing P/E of 35.9 (trailing EPS ₹54.2).
- Q1 FY27 results (consolidated, filed 13 Aug 2026): revenue ₹2,788 crore (+20.8% year on year), net profit ₹424 crore (+82.2%); the price moved -3.5% on the first session after.
- Promoters held 44.72% at 30 Jun 2026, unchanged on the previous filing.
- Q2 FY27 results are expected between 10 Nov 2026 and 14 Nov 2026, going by past filing dates — an estimate, not an announcement.
About
CSVMacro sectorHealthcare
Basic industryPharmaceuticals
ISININE571A01038
SeriesEQ
Listed8 Feb 1995
History from2 Jan 1995
Sessions7,836
Turnover rank#490
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.
More in Pharmaceuticals & Biotechnology
CSV- DIVISLABDivi's Laboratories Limited9,550.00+3.85%
- LAURUSLABSLaurus Labs Limited2,050.00+3.99%
- SUNPHARMASun Pharmaceutical Industries Limited1,804.10+1.37%
- WOCKPHARMAWockhardt Limited2,176.40+5.47%
- DRREDDYDr. Reddy's Laboratories Limited1,208.00+0.42%
- MOREPENLABMorepen Laboratories Limited143.96+6.41%
- ZYDUSLIFEZydus Lifesciences Limited1,159.50+1.80%
- SYMBIOTECSYMBIOTEC1,149.50-1.73%
- TORNTPHARMTorrent Pharmaceuticals Limited4,772.000.00%
- GLANDGland Pharma Limited3,006.10+3.25%
- LUPINLupin Limited2,029.30+0.91%
- AUROPHARMAAurobindo Pharma Limited1,692.80+1.07%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE